Current Edition


Recent FDA Advancements in Rare Diseases – Funding, Partnerships, and Programs

The paucity of therapeutic choices is a reality often acknowledged by the US Food and Drug Administration (FDA) as it reviews applications for new medical …

Continue Reading →

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine

The COVID-19 pandemic is creating a $100 billion pharma goliath. Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s …

Continue Reading →

Results of the Randomized, Double-Blind, Placebo-Controlled, Phase III HERCULES study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura to be presented at he 59th Annual Meeting of the American Society of Hematology

Ablynx NV [Euronext Brussels and Nasdaq: ABLX] has announced that results from its Phase III HERCULES study of caplacizumab have been selected as one of only six …

Continue Reading →